There might be a ton of different things that human beings do well, but there is nothing we do better than growing on a consistent basis. This, in particular, has allowed us to hit upon some huge milestones, with technology appearing as a major part of the stated group. The reason why technology gets to be such a standout is, by and large, inspired by the creation’s unprecedented skill-set. However, it is also somewhat predicated upon the manner in which those skills were used. Now that we think about it, the latter component was, in fact, what gave technology a spectrum-wide presence, including a very well-timed appearance on our healthcare block. We call technology’s foray into healthcare well-timed because it materialized right when the sector was starting to struggle against its obsolete structure. This reality, of course, will change big time under the new regime, but even after reinventing the sector’s identity, the famous medtech concept will continue to produce all the right goods. If anything, the stated pattern should only grow stronger on the back of a recent funding.
Health data company CuriMeta has successfully secured over $6 million in seed financing. The raise, which was led by BJC HealthCare and the Washington University School of Medicine (WashU Medicine), is expected to finance the company’s goal of improving research data picture for healthcare providers and life sciences manufacturers. You see, most EHR (electronic health record) data is optimized for care delivery and not research, something that makes the whole process a lot more tedious, and even inaccurate at times. CuriMeta, on its part, wants to solve that problem by cleansing, curating, and annotating data on various disease states for its clients so that they can close their evidence cycles more quickly while developing new interventions.
“We are creating advanced real world data because we want to provide researchers with a much more complete and comprehensive view of human biology and the impact that treatments have on groups of patients and on the nature of a disease itself,” said Davis Walp, founder and CEO of CuriMeta. “We’re creating 360-degree surround sound views of patient populations that researchers can use to really move the needle forward.”
Beyond revamping the nature and quality of the data, CuriMeta is also focused on ensuring its security. Talk about how it plans on approaching the stated element; the company will use artificial intelligence to create synthetic datasets. This should help in regards to storing the data in a safer place, and consequentially, reducing the risk of a breach.
CuriMeta’s close relationship with BJC and WashU Medicine is also an important part of the company’s future. The partners’ heavy expertise and their huge line-up of experts can assist the St Louis-based company in providing various studies with an extra edge that maybe many of its direct competitors can’t conceive.
